Monday Health and Wellness Platform Hims & Hers Health Co., Ltd. (NYSE:HIMS) stock rose after the company announced it was adding a GLP-1 injection to its weight loss portfolio.
The company currently offers access to GLP-1 injectables and weight management oral drug kits.
The availability of formulated GLP-1 means that eligible customers can use medicines containing the same active ingredients. Novo Nordisk A/S (NYSE:NVO) Ozempic and Wegovy cannot avoid the shortages and costs that currently limit access to branded drugs.
Through our partnership with the U.S. manufacturer of generic drugs and 503B compound injectables, Hims & Hers can help millions of obese patients.
Hims & Hers expects its weight loss program to generate more than $100 million in revenue by the end of 2025.
GLP-1 injections are shipped from Hims & Hers partner pharmacies.
Once stable supply becomes available through pharmacy wholesalers, Hims & Hers will make branded options available to customers, expanding its offering beyond its current oral medication kits and formulated GLP-1 injectables. It’s a schedule.
Weight loss drugs cost $79 per month for oral drug kits and $199 per month for combination GLP-1 injections.
Price includes unlimited medical consultations with licensed providers.
Oral drug kits and compounded GLP-1 injections are not available in all states.
Price action: HIMS stock is up 34.9% at $19.65 at last check on Monday.
Photo by Vidmir Rais via Pixabay
“The Active Investor’s Secret Weapon” Step up your stock market game with the #1 News & Everything else trading tool: Benzinga Pro – Click here to start your 14-day trial now!
Want the latest stock analysis from Benzinga?
This article Wellness platform Hims & Hers Health adds GLP-1 injection for weight loss, stock price soars
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
